Omslagafbeelding van de show Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Podcast door Talking About Tumors

Engels

Technologie en Wetenschap

Probeer 14 dagen gratis

€ 9,99 / maand na proefperiode.Elk moment opzegbaar.

  • 20 uur luisterboeken / maand
  • Podcasts die je alleen op Podimo hoort
  • Gratis podcasts
Probeer gratis

Over Talking About Tumors with Ryann and Ryan - A medical oncology podcast

Designed for residents and fellows to provide an overview of the clinical practice and evidence behind management of each individual tumor site. Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, cancer

Alle afleveringen

50 afleveringen

aflevering 05_02 Neuroendocrine Tumors artwork

05_02 Neuroendocrine Tumors

1. Nomenclature, unique considerations 2. Secretory Syndromes 3. Somatostatin directed therapy 4. Peptide Receptor Radionucleotide Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1–10 1.   Kunz PL  et al. Journal of Clinical Oncology. 2023;41(7):1359-1369. doi:10.1200/JCO.22.01013/ 2.  Strosberg JR et al. Lancet Oncol. 2021;22(12):1752-1763. doi:10.1016/S1470-2045(21)00572-6 3.  Strosberg J  et al. NEJM. 2017;376(2):125-135. doi:10.1056/NEJMOA1607427/ 4.  Caplin ME et al. NEJM. 2014;371(3):224-233. doi:10.1056/NEJMOA1316158/ 5.   Caplin ME et al. Endocrine. 2021;71(2):502-513. doi:10.1007/S12020-020-02475-6.  Neuroendocrine Tumor Guidelines, ESMO. Accessed May 1, 2025. https://www.esmo.org/guidelines/guidelines-by-topic/esmo-clinical-practice-guidelines-endocrine-and-neuroendocrine-cancers 7.   Pieterman CRC  , et al. J Neuroendocrinol. Published online January 1, 2024. doi:10.1111/JNE.13468 8.   NANETS. Accessed May 1, 2025. https://nanets.net/ 9.  Rinke A et al. Results of long-term survival. Neuroendocrinology. 2016;104(1):26-32. doi:10.1159/000443612, 10. Rinke A et al. J Clin Oncol. 2009;27(28):4656-4663. doi:10.1200/JCO.2009.22.8510,   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

3 mei 2025 - 27 min
aflevering 05_01 Hepatocellular carcinoma artwork

05_01 Hepatocellular carcinoma

1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.           Finn RS, et al. Oncologist. 2022;27(12):E938-E948. doi:10.1093/ONCOLO/OYAC183 2.           Pfister D et al. Nature 2021 592:7854. 2021;592(7854):450-456. doi:10.1038/s41586-021-03362-0 3.           Zhu AX  et al. Lancet Oncol. 2019;20(2):282-296. doi:10.1016/S1470-2045(18)30937-9 4.           Abou-Alfa GK, et al. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDOA2100070 5.           Kudo M, et al. Lancet. 2018;391(10126):1163-1173. doi:10.1016/S0140-6736(18)30207-1 7.           Llovet JM, et al. NEJM. 2008;359(4):378-390. doi:10.1056/NEJMOA0708857 8.           Reig M, et al.. J Hepatol. 2022;76(3):681-693. doi:10.1016/J.JHEP.2021.11.018 9.           Cheng AL et al.  J Hepatol. 2022;76(4):862-873. doi:10.1016/j.jhep.2021.11.030 10.        Finn RS et al. NEJM. 2020;382(20):1894-1905. doi:10.1056/NEJMOA1915745/ 11.        Rose S, et al. Lancet. 2024;404(10453):656-657. doi:10.1016/S0140-6736(24)00800-6   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

19 dec 2024 - 32 min
aflevering 04_10 Testicular Cancer II artwork

04_10 Testicular Cancer II

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer.   1.          Pico JL et al. Ann Oncol. 2005;16(7):1152-1159. doi:10.1093/ANNONC/MDI228 2.          Adra N, et al. J Clin Oncol. 2017;35(10):1096-1102. doi:10.1200/JCO.2016.69.5395 3.          Nichols CR et al. J Clin Oncol. 1998;16(4):1287-1293. doi:10.1200/JCO.1998.16.4.1287 4.          de Wit R et al.. JCO. 1997;15(5):1837-1843. doi:10.1200/JCO.1997.15.5.1837 5.          Culine S, et al.  Ann Oncol. 2007;18(5):917-924. doi:10.1093/ANNONC/MDM062 6.          Lorch A, et al. Journal of Clinical Oncology. 2007;25(18_suppl):5086-5086. doi:10.1200/JCO.2007.25.18_SUPPL.5086 7.          Fung C, et al.. J Natl Compr Canc Netw. 2019;17(12):1557-1568. doi:10.6004/JNCCN.2019.7369   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

27 okt 2024 - 25 min
aflevering 04_09 Testicular Cancer I artwork

04_09 Testicular Cancer I

1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease   Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1.          Hiester A et al. Eur J Cancer. 2021;155:64-72. doi:10.1016/J.EJCA.2021.06.022 2.          Calaway AC et al. Eur Urol. 2019;76(5):607-609. doi:10.1016/j.eururo.2019.05.031 3.          Oliver RTD et al. J Clin Oncol. 2011;29(8):957-962. doi:10.1200/JCO.2009.26.4655 4.          Oliver RTD et al. Lancet. 2005;366(9482):293-300. doi:10.1016/S0140-6736(05)66984-X 5.          Joffe JK et al. JCO. 2022;40(22):2468-2478. doi:10.1200/JCO.21.01199/ 6.          Bhatia S et al.. J NCCN. 2023;21(8):851-880. doi:10.6004/JNCCN.2023.0040 7.          Stephenson A et al. J Urol. 2019;202(2):272-281. doi:10.1097/JU.0000000000000318     Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

18 sep 2024 - 28 min
aflevering 04_08 Metastatic Renal Cell Carcinoma artwork

04_08 Metastatic Renal Cell Carcinoma

1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com.  We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practice.  DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology. 10th edition. Philadelphia: Wolters Kluwer, 2015. Uptodate.com Waltham, MA: Wolters Kluwer. 1. Flanigan RC et al.  J Urol.  2004;171(3):1071-6. doi:10.1097/01.ju0000110610.61545.ae 2. Bex A et al. JAMA Oncology. 2019;5(2):164-170.  doi:10.1001/jamaoncol.2018.5545 3. Mejean A et al. NEJM.  2018;379:417-427. doi:10.1056/NEJMoa1803675 4. Motzer RJ et al.  NEJM.  2007;356:115-124. doi:10.1056/NEJMoa065044 5. Rini BI et al.  NEJM.  2019;380:1116-1127. doi:10.1056/NEJMoa1816714 6. Rini BI et al. JCO.  2023;41(17 Supp).  doi:10.1200/JCO.2023.41.17_suppl.LBA4501 7. Kartolo et al. Urology. 2021;157:8-14. doi:10.1016/j.urology.2021.08.023 8. Motzer RJ et al. NEJM. 2018;378:1277-1290.  doi:10.1056/NEJMoa1712126 9. Motzer R et al.  NEJM.  2021;384:1289-1300.  doi:10.1056/NEJMoa2035716 10. Albiges L et al.  Ann Oncol.  2023;34(2 Supp):S1329-S1330.  doi:10.1016/j.annonc.2023.10.090 11. Jonasch E.  ASCO Annual Meeting presented May 31, 2024 in Chicago, IL   Disclosures Talking about Tumors with Ryan and Ryann is not medical advice.  We have received no funding in relation to the information discussed within this episode and have no financial conflicts of interest to disclose.  All opinions are those of whoever stated them.  We have compiled this podcast to serve as an introduction to the field of medical oncology for post-graduate trainees interested in the topic.  Tags Hematology/Oncology, evidence based medicine, education, chemotherapy, immunotherapy, medical oncology

2 aug 2024 - 24 min
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Super app. Onthoud waar je bent gebleven en wat je interesses zijn. Heel veel keuze!
Makkelijk in gebruik!
App ziet er mooi uit, navigatie is even wennen maar overzichtelijk.

Kies je abonnement

Meest populair

Premium

20 uur aan luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 14 dagen gratis
Daarna € 9,99 / maand

Probeer gratis

Premium Plus

Onbeperkt luisterboeken

  • Podcasts die je alleen op Podimo hoort

  • Geen advertenties in Podimo shows

  • Elk moment opzegbaar

Probeer 30 dagen gratis
Daarna € 13,99 / maand

Probeer gratis

Alleen bij Podimo

Populaire luisterboeken

Veelgestelde vragen

Meer vragen & antwoorden
Probeer gratis

Probeer 14 dagen gratis. € 9,99 / maand na proefperiode. Elk moment opzegbaar.